--- title: "SPAC Mergers, Biotech Trials, and Supply Chain Shifts Reshape the Fringe Market" type: "News" locale: "en" url: "https://longbridge.com/en/news/297164741.md" description: "From SPACs executing new mergers to biotech firms advancing critical clinical trials, a quiet reshuffling is happening among under-the-radar equities. Chip packaging and solar manufacturing are also seeing steady demand amid broader tech shifts." datetime: "2026-08-27T10:13:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297164741.md) - [en](https://longbridge.com/en/news/297164741.md) - [zh-HK](https://longbridge.com/zh-HK/news/297164741.md) generator: "portal-rs" --- # SPAC Mergers, Biotech Trials, and Supply Chain Shifts Reshape the Fringe Market While the broader market fixates on mega-caps, a flurry of activity is reshaping under-the-radar equities. From special purpose acquisition companies finalizing new targets to biotech firms pushing critical clinical trials, the fringe of the market is undergoing a quiet but significant transition. In the SPAC arena, **Feutune Light Acquisition Corporation (FLTW.US)** is pushing forward with its merger. Shareholders overwhelmingly approved a combination with Thunder Power Holdings, paving the way for the new entity to trade under the AIEV ticker. The move comes as Thunder Power eyes the acquisition of 16 solar power plants in Taiwan. On the flip side of the SPAC coin, **Aetherium Acquisition Corp. (AEHG.US)** faced a setback, receiving notice that its business combination agreement with Capital A Berhad has been terminated. The push for domestic manufacturing and digital infrastructure remains a persistent theme. **Axtel (AXTL.US)**, the Mexican telecom operator, reported a 17% sequential boost in its Q2 2026 comparable EBITDA, driven by operational efficiencies. The company is actively building cross-border networks to support hyperscale data centers. Meanwhile, **Graphene & Solar Technologies (GRSD.US)** is attempting to bring solar manufacturing back to the US. A recent USD 40 million convertible note offering and a hefty USD 45 million tax credit for California projects indicate momentum, despite currently reporting zero revenue. In the semiconductor space, packaging and testing provider **ChipMOS TECHNOLOGIES (IMOS.US)** hit a major milestone, with Q2 2026 revenue reaching its highest level since 2014. The company cites ongoing AI-driven demand imbalances extending visibility well into the year. Biotech and healthcare names are seeing their own shifts. **NervGen Pharma (NGEN.US)** is advancing its NVG-291 therapy for spinal cord injuries, recently completing a USD 60 million public offering to support its trials. **Galmed Pharmaceuticals (GLMD.US)**, historically focused on NASH treatments, is reorganizing with a proposed name change to Eocene Ltd. and an acquisition aimed at the European market. Finally, resource extraction and niche ETFs round out the movement. **Seabridge Gold (SA.US)** posted a massive Q2 2026 net income bump thanks to the divestiture of its Courageous Lake project, while **Western Copper and Gold Corporation (WRN.US)** secured a USD 92 million offering to advance its Casino project in the Yukon. In the cannabis sector, the **AdvisorShares Pure US Cannabis ETF (MSOX.US)** continues to offer leveraged exposure for traders betting on regulatory shifts in the US market. ### Related Stocks - [GRSD.US](https://longbridge.com/en/quote/GRSD.US.md) - [NGEN.US](https://longbridge.com/en/quote/NGEN.US.md) - [IMOS.US](https://longbridge.com/en/quote/IMOS.US.md) - [SA.US](https://longbridge.com/en/quote/SA.US.md) - [GLMD.US](https://longbridge.com/en/quote/GLMD.US.md) - [WRN.US](https://longbridge.com/en/quote/WRN.US.md) - [EOCN.US](https://longbridge.com/en/quote/EOCN.US.md) ## Related News & Research - [NGEN: NVG-291 demonstrated significant functional gains in chronic SCI and advances to a pivotal Phase 3 trial](https://longbridge.com/en/news/300611156.md) - [Seabridge Gold Flags KSM JV Progress, 72-Year Mine Potential at Denver Gold Forum](https://longbridge.com/en/news/300522902.md) - [NervGen Pharma Flags Non-Cash Accounting Errors, Orders Restatement of 2024–2026 Results](https://longbridge.com/en/news/300165378.md) - [NervGen to Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments | NGEN Stock News](https://longbridge.com/en/news/300164119.md) - [Western Copper and Gold Announces Casino Project Selected for Canada Investment Summit Prospectus | WRN Stock News](https://longbridge.com/en/news/298913160.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**